ijms-logo

Journal Browser

Journal Browser

Novel Biosystems in Toxicology and Pharmacology

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 9256

Special Issue Editors


E-Mail Website
Guest Editor
1. ESTG-Polytechnic Institute of Leiria, Morro do Lena, Alto do Vieiro, 2411-901 Leiria, Portugal
2. UCIBIO-NOVA, University of Lisbon, 2829-516 Lisboa, Portugal
Interests: natural bioactive compounds; biopolymer applications; drug-delivery systems; environmental toxicants
Special Issues, Collections and Topics in MDPI journals

E-Mail Website1 Website2
Guest Editor
1. Faculdade de Ciências e Tecnologia (FCT), Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal; 2. CCMAR, Campus de Gambelas, Universidade do Algarve, 8005-139 Faro, Portugal
Interests: metals in molecular sciences; decavanadate biochemistry; polyoxometalate (POM) interactions with proteins; metals and biomedical applications
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Departamento Ciências da Vida, Nova School of Science and Technology (FCT-Nova), Nova University of Lisbon, 2829-516 Caparica, Portugal
Interests: glycobiology; cancer; congenital disorders of glycosylation; cancer immunotherapy; antibodies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biological systems and models provide essential platforms for the evaluation of drugs and toxicants. From biomolecular systems comprising enzymes or antibodies to a panoply of existing cell culture models, different bio-based systems have become important tools to study toxicological and pharmacological responses. The significant progresses that have been made in health care, drug development and food and environmental safety have not left in vitro approaches by the wayside. On the contrary, keeping pace with biological knowledge and biofabrication technologies, the expectations are high in the development of novel, multifunctional, integrated, accessible and increasingly bio-informative methods and devices.

This Special Issue aims to stimulate research on the development and applications of biomolecular systems. Some topics in the crossroads of Toxicology and Pharmacology are initially set to promote the exchange of ideas, but other concepts and practical approaches addressing issues in those fields, and Molecular Biosciences in general, are welcome.

Topics of interest include, but are not limited to:

-Cell culture systems replicating in vivo conditions;

-Biodevices and functional tissues for disease modelling;

-Target identification and network pharmaco/toxicology ;

-Non-animal and human-relevant approaches;

-Barrier mimicking and drug delivery systems ;

-Bioactive compounds and materials;

-Responses to mixtures, emergent pollutants, food ingredients and impurities in pharmaceuticals;

-Biosensors for diagnostic, environmental and industrial applications;

-Development of vaccines and cell therapies; 

-Integration with modelling and computational methods.

 

This Special Issue runs in parallel to the meeting on Biosystems in Toxicology and Pharmacology (https://sciforum.net/event/BiTaP). Participants in the meeting will be offered a discount on the Journal’s APC, but the Special Issue is open to all quality manuscripts under the above research scope.

We invite all who are interested in the development of new bioanalytical and research methods to submit their research to this Special Issue. 

Dr. Ricardo Lagoa
Prof. Dr. Manuel Aureliano
Prof. Paula A. Videira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 4336 KiB  
Article
Finding New Molecular Targets of Two Copper(II)-Hydrazone Complexes on Triple-Negative Breast Cancer Cells Using Mass-Spectrometry-Based Quantitative Proteomics
by Lucia M. Balsa, María R. Rodriguez, Verónica Ferraresi-Curotto, Beatriz S. Parajón-Costa, Ana C. Gonzalez-Baró and Ignacio E. León
Int. J. Mol. Sci. 2023, 24(8), 7531; https://doi.org/10.3390/ijms24087531 - 19 Apr 2023
Cited by 8 | Viewed by 1524
Abstract
Breast cancer is the most common cancer in women, with a high incidence estimated to reach 2.3 million by 2030. Triple-Negative Breast Cancer (TNBC) is the greatest invasive class of breast cancer with a poor prognosis, due to the side-effects exerted by the [...] Read more.
Breast cancer is the most common cancer in women, with a high incidence estimated to reach 2.3 million by 2030. Triple-Negative Breast Cancer (TNBC) is the greatest invasive class of breast cancer with a poor prognosis, due to the side-effects exerted by the chemotherapy used and the low effectivity of novel treatments. In this sense, copper compounds have shown to be potentially effective as antitumor agents, attracting increasing interest as alternatives to the usually employed platinum-derived drugs. Therefore, the aim of this work is to identify differentially expressed proteins in MDA-MB-231 cells exposed to two copper(II)-hydrazone complexes using label-free quantitative proteomics and functional bioinformatics strategies to identify the molecular mechanisms through which these copper complexes exert their antitumoral effect in TNBC cells. Both copper complexes increased proteins involved in endoplasmic reticulum stress and unfolded protein response, as well as the downregulation of proteins related to DNA replication and repair. One of the most relevant anticancer mechanisms of action found for CuHL1 and CuHL2 was the down-regulation of gain-of-function-mutant p53. Moreover, we found a novel and interesting effect for a copper metallodrug, which was the down-regulation of proteins related to lipid synthesis and metabolism that could lead to a beneficial decrease in lipid levels. Full article
(This article belongs to the Special Issue Novel Biosystems in Toxicology and Pharmacology)
Show Figures

Figure 1

Review

Jump to: Research

29 pages, 3332 KiB  
Review
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs
by Michał Nicze, Maciej Borówka, Adrianna Dec, Aleksandra Niemiec, Łukasz Bułdak and Bogusław Okopień
Int. J. Mol. Sci. 2024, 25(2), 815; https://doi.org/10.3390/ijms25020815 - 09 Jan 2024
Viewed by 2083
Abstract
Drugs based on peptides and proteins (PPs) have been widely used in medicine, beginning with insulin therapy in patients with diabetes mellitus over a century ago. Although the oral route of drug administration is the preferred one by the vast majority of patients [...] Read more.
Drugs based on peptides and proteins (PPs) have been widely used in medicine, beginning with insulin therapy in patients with diabetes mellitus over a century ago. Although the oral route of drug administration is the preferred one by the vast majority of patients and improves compliance, medications of this kind due to their specific chemical structure are typically delivered parenterally, which ensures optimal bioavailability. In order to overcome issues connected with oral absorption of PPs such as their instability depending on digestive enzymes and pH changes in the gastrointestinal (GI) system on the one hand, but also their limited permeability across physiological barriers (mucus and epithelium) on the other hand, scientists have been strenuously searching for novel delivery methods enabling peptide and protein drugs (PPDs) to be administered enterally. These include utilization of different nanoparticles, transport channels, substances enhancing permeation, chemical modifications, hydrogels, microneedles, microemulsion, proteolytic enzyme inhibitors, and cell-penetrating peptides, all of which are extensively discussed in this review. Furthermore, this article highlights oral PP therapeutics both previously used in therapy and currently available on the medical market. Full article
(This article belongs to the Special Issue Novel Biosystems in Toxicology and Pharmacology)
Show Figures

Figure 1

21 pages, 14902 KiB  
Review
Polyoxometalates Impact as Anticancer Agents
by Fátima Carvalho and Manuel Aureliano
Int. J. Mol. Sci. 2023, 24(5), 5043; https://doi.org/10.3390/ijms24055043 - 06 Mar 2023
Cited by 16 | Viewed by 4494
Abstract
Polyoxometalates (POMs) are oxoanions of transition metal ions, such as V, Mo, W, Nb, and Pd, forming a variety of structures with a wide range of applications. Herein, we analyzed recent studies on the effects of polyoxometalates as anticancer agents, particularly their effects [...] Read more.
Polyoxometalates (POMs) are oxoanions of transition metal ions, such as V, Mo, W, Nb, and Pd, forming a variety of structures with a wide range of applications. Herein, we analyzed recent studies on the effects of polyoxometalates as anticancer agents, particularly their effects on the cell cycle. To this end, a literature search was carried out between March and June 2022, using the keywords “polyoxometalates” and “cell cycle”. The effects of POMs on selected cell lines can be diverse, such as their effects in the cell cycle, protein expression, mitochondrial effects, reactive oxygen species (ROS) production, cell death and cell viability. The present study focused on cell viability and cell cycle arrest. Cell viability was analyzed by dividing the POMs into sections according to the constituent compound, namely polyoxovanadates (POVs), polyoxomolybdates (POMos), polyoxopaladates (POPds) and polyoxotungstates (POTs). When comparing and sorting the IC50 values in ascending order, we obtained first POVs, then POTs, POPds and, finally, POMos. When comparing clinically approved drugs and POMs, better results of POMs in relation to drugs were observed in many cases, since the dose required to have an inhibitory concentration of 50% is 2 to 200 times less, depending on the POMs, highlighting that these compounds could become in the future an alternative to existing drugs in cancer therapy. Full article
(This article belongs to the Special Issue Novel Biosystems in Toxicology and Pharmacology)
Show Figures

Figure 1

Back to TopTop